Clinical Trial Update: A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II) [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 trial of JNJ-56136379, evaluating safety, tolerability, and pharmacokinetics in healthy participants and in in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• JNJ-56136379

Snippet

Sponsor: Janssen Sciences Ireland UC | Conditions: Healthy, Hepatitis, Chronic | Phase 1 | Status: COMPLETED